U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07776743) titled 'A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis' on Aug. 07.
Brief Summary: This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive relapsing-remitting multiple sclerosis (RRMS). Approximately 30 subjects with RRMS will be enrolled and randomized 2:1 to receive rocbrutinib 25 mg once daily (experimental arm) or dimethyl fumarate (DMF) delayed-release capsules 120 mg twice daily, escalated to 240 mg twice daily after 7 days (active control ...